Complete Guide to Arthritis Medications

Two Major Types of Arthritis

Osteoarthritis (OA) is the most common joint condition — caused by gradual breakdown of cartilage (the cushioning between joint surfaces) over time. It affects hips, knees, hands, and spine most often. Pain is mechanical — worse with activity, better with rest. The primary damage is structural, and current medications manage symptoms rather than slowing cartilage loss.

Rheumatoid arthritis (RA) is an autoimmune disease — the immune system attacks the synovial lining of joints, causing inflammation, swelling, pain, and eventually joint erosion. It affects joints symmetrically (both hands, both feet) and causes systemic symptoms (fatigue, fever). Without treatment, RA progressively damages joints and increases cardiovascular risk. Medications can suppress the disease itself.

This distinction is fundamental: OA is managed with symptom relief; RA requires disease modification.

Osteoarthritis Medications

For OA, the goal is pain control and functional improvement:

• Acetaminophen: First choice for mild-to-moderate OA pain; safe with long-term use at appropriate doses; less effective for severe pain.
• Topical NSAIDs (diclofenac gel/Voltaren): Apply directly to affected joints; effective for hand and knee OA with minimal systemic side effects.
• Oral NSAIDs (ibuprofen, naproxen, celecoxib): Effective for moderate-to-severe OA pain and inflammation; carry GI, cardiovascular, and kidney risks with regular use.
• Duloxetine (Cymbalta): An SNRI approved for chronic musculoskeletal pain including OA — particularly useful when pain has a central sensitization component.
• Intra-articular injections: Corticosteroid injections provide short-term pain relief (weeks to months); hyaluronic acid injections have inconsistent evidence.
• Opioids: Generally avoided due to poor long-term outcomes in OA and significant risks; reserved for severe cases when surgery is not an option.

Conventional DMARDs for Rheumatoid Arthritis

Disease-modifying antirheumatic drugs (DMARDs) suppress the immune system to slow or halt joint destruction in RA — a fundamentally different goal from OA treatment.

Conventional (non-biologic) DMARDs include: - Methotrexate (most important — see below) - Hydroxychloroquine (Plaquenil): An antimalarial with modest immunomodulatory effects; used in mild RA or in combination. Well tolerated but requires regular eye exams (rare retinal toxicity with long-term use). - Sulfasalazine: Anti-inflammatory effect; used in mild-to-moderate RA often combined with other agents. - Leflunomide: Alternative to methotrexate or used in combination; inhibits pyrimidine synthesis.

Methotrexate: The Anchor Drug

Methotrexate (MTX) is the most important and most used DMARD for RA globally. It inhibits folate metabolism, suppressing rapidly dividing immune cells involved in RA inflammation.

Used weekly (not daily — this is common and important), typically 15–25 mg/week. Always co-prescribed with folic acid supplementation to reduce side effects (mouth sores, nausea, hair loss).

Monitoring requirements: - Regular blood tests to check liver function and blood counts - Avoid alcohol (additive liver toxicity) - Contraindicated in pregnancy (teratogenic — causes birth defects)

MTX takes 6–12 weeks to show its full effect. When biologics are added to a regimen, they are almost always combined with methotrexate — the combination is significantly more effective than either alone.

Biologic DMARDs

Biologic drugs are large protein molecules manufactured from living cells, engineered to target specific immune system components driving RA inflammation. They are far more targeted than conventional DMARDs.

TNF Inhibitors

TNF (tumor necrosis factor) is a key cytokine driving RA inflammation. TNF inhibitors were the first biologics for RA and remain widely used.

Examples: etanercept (Enbrel), adalimumab (Humira), infliximab (Remicade), certolizumab (Cimzia), golimumab (Simponi).

They substantially reduce joint inflammation and slow radiographic progression. Serious risks include increased susceptibility to infections (especially tuberculosis — screening required before starting) and reactivation of latent hepatitis B.

Other Biologic Targets

• IL-6 inhibitors (tocilizumab/Actemra, sarilumab/Kevzara): Block interleukin-6, another major inflammatory cytokine. Effective in TNF-inadequate responders.
• B-cell depletion (rituximab/Rituxan): Destroys CD20-positive B cells; used when other biologics fail.
• T-cell co-stimulation blocker (abatacept/Orencia): Prevents T-cell activation.
• IL-17 inhibitors (secukinumab, ixekizumab): Used more in psoriatic arthritis and ankylosing spondylitis than RA.

JAK Inhibitors

JAK (Janus kinase) inhibitors are small-molecule drugs that block intracellular signaling pathways critical to multiple inflammatory cytokines simultaneously. Unlike biologics, they are oral.

Examples: tofacitinib (Xeljanz), baricitinib (Olumiant), upadacitinib (Rinvoq), filgotinib.

JAK inhibitors are as effective as TNF inhibitors in many patients and offer the convenience of oral dosing. However, they carry specific safety concerns that have led to updated FDA warnings:

• Increased risk of serious infections
• Increased risk of blood clots (venous thromboembolism)
• Possible increased cardiovascular events and cancer risk (especially with tofacitinib at higher doses)

Current guidelines generally recommend using TNF inhibitors or other biologics before JAK inhibitors for most patients, particularly those with cardiovascular risk factors.

Biosimilars in Rheumatology

Biosimilars are approved copies of reference biologics that are highly similar in safety and effectiveness. Biologics like adalimumab (Humira) were extremely expensive; the entry of biosimilars (biosimilarBiosimilar

A biologic drug that is highly similar to an already approved reference biologic product, with no clinically meaningful differences in safety, purity, or potencyPotency

The amount of drug needed to produce a given effect. A more potent drug achieves the same effect at a lower dose. Potency is different from efficacy — a drug can be highly potent but have limited maxi

. Unlike generics (which are chemically

adalimumab products) has created significant price competition.

In 2023, multiple biosimilars for adalimumab entered the US market — the first time competition was possible for the world's best-selling drug. Biosimilar uptake in rheumatology is growing because:

• Cost savings can be substantial for patients and payers
• FDA approval requires rigorous demonstration of biosimilarity
• Switching between a reference biologic and its biosimilar is generally considered safe

Switching should be discussed with your rheumatologist — clinical guidelines increasingly support interchangeability but monitoring after switching is recommended.

Combination DrugCombination Drug

A single pharmaceutical product containing two or more active ingredients, designed to improve efficacyEfficacy

The maximum therapeutic effect a drug can produce, regardless of the dose given. A drug with higher efficacy can achieve a greater maximum response than one with lower efficacy, even if the latter is

, reduce side effects, or simplify dosing. Fixed-dose combinations are increasingly used to impro

Strategies

RA treatment increasingly uses combination drug therapy for better outcomes:

• Methotrexate + biologic: The most evidence-backed combination; consistently outperforms monotherapy
• Triple therapy (methotrexate + sulfasalazine + hydroxychloroquine): Can be as effective as biologic combinations at lower cost for some patients
• Methotrexate + JAK inhibitor: Effective but carries combined immunosuppression risks

The treat-to-target approach — setting explicit remission or low-disease-activity goals and stepping up treatment until the target is reached — has transformed RA outcomes over the past decade.

Corticosteroids: Powerful but Limited

Oral corticosteroids (prednisone) and injectable steroids are extremely effective at rapidly reducing RA inflammation. They are used as bridge therapy — providing fast relief while DMARDs take weeks to months to reach effect.

Long-term use is discouraged because of serious side effects: osteoporosis, diabetes, cataracts, adrenal suppression, weight gain, and cardiovascular disease. The goal is to minimize cumulative steroid exposure by using the lowest dose for the shortest time needed.

Intra-articular steroid injections directly into an inflamed joint can provide weeks of localized relief without significant systemic exposure.

Key Takeaways

• Osteoarthritis is managed with symptom relief — analgesics, topical NSAIDs, and joint injections. No drug currently slows OA progression.
• Rheumatoid arthritis requires disease-modifying drugs — starting with methotrexate, which remains the anchor of therapy.
• Biologics (especially TNF inhibitors) dramatically changed RA outcomes by targeting specific immune pathways; they require infection screening and monitoring.
• JAK inhibitors are effective oral alternatives to biologics but carry specific cardiovascular and clotting risks.
• Biosimilars have entered the rheumatology market for major biologics, making previously expensive treatments more affordable.
• Combination therapy — particularly methotrexate with a biologic — is the evidence-based standard for moderate-to-severe RA.
• Corticosteroids provide fast relief but are a bridge, not a long-term strategy.